Vidyya Medical News Servicesm
Vidyya, from the Sanskrit "vaidya," a practitioner who has come to understand the science of life.

Volume 2 Published - 14:00 UTC    08:00 EST    06-March-2001      
Issue 65 * Next Update - 14:00 UTC 08:00 EST    07-March-2001      

Vidyya Home  Vidyya

Home Of Our Sponsor, Vidyya.  Vidyya. Home

Vidyya Archives  Vidyya Archives

Search Vidyya  Search Vidyya

Visit Our Library  Ex Libris

Subscribe To Our News Service  Subscriptions

All About Us  About Vidyya

Back To Vidyya Today In Vidyyasm

Vidyya Medical News Service For 06-March-2001:

The following stories appear in full on Today's Vidyya Medical News Service Web site.

The FDA is advising women who take the prescription blood-thinner warfarin to consult their doctor or pharmacist for advice before using an OTC vaginal miconazole product. The FDA is taking this action because the agency has received two adverse events indicating abnormal blood clotting tests with women who took anticoagulant therapy and used vaginal miconazole.

For more information: Safety Warning: Miconazole Vaginal Cream And Suppositories

Data presented at the 59th Annual American Academy of Dermatology (AAD) meeting support the further study of the efficacy and safety of ASM 981 (pimecrolimus) oral tablet in the treatment of adult patients with moderate to severe chronic plaque psoriasis. An ascomycin macrolactam, ASM 981 is a selective inflammatory cytokine inhibitor that is being developed by Novartis Pharmaceuticals Corporation specifically for the treatment of inflammatory skin diseases.

For more information: Study Supports Potential Oral Treatment For Psoriasis Sufferers

Serono SA announced yesterday that its US affiliate has been granted marketing authorization from the US Food and Drug Administration (FDA) for a new multi-dose presentation of Gonal-F® (follitropin alfa for injection), the most prescribed gonadotropin for treating infertile couples in the world. Gonal-F Multi-Dose will be available with flexible dosing and a one-step drug preparation process that uses a liquid for use over several days of treatment. Furthermore, Gonal-F® Multi-Dose can be injected more quickly due to reduced drug volume per injection. The product will be introduced this Spring.

For more information: Gonal-F® Multi-Dose Receives FDA Approval For Treatment Of Infertility

Gonal-F®, a highly pure FSH manufactured by recombinant DNA technology, acts directly on the ovaries to help stimulate the development of follicles. It is also the hormone responsible for sperm production in men. Gonal-F® can be administered subcutaneously (just under the skin) using a small needle. Get the full prescribing information in today's Vidyya.

For more information: Prescribing Information: Gonal-F®

An international panel of sleep experts issued new insomnia management guidelines, published in this month's issue of the International Journal of Clinical Practice, to address the underdiagnosis and insufficient treatment of the common sleep disorder. The guidelines were developed in response to a lack of awareness of insomnia, despite its high prevalence. In fact, most Americans have never initiated a conversation about sleep problems with a doctor, and nearly two-thirds say doctors have not asked how well they sleep, according to a recent National Sleep Foundation survey.

For more information: International Sleep Experts Issue New Guidelines For Improving The Diagnosis And Treatment Of Insomnia

Today's Vidyya articles are:

As always, we hope you enjoy the issue.

Vidyya. Home |  Ex Libris |  Vidyya  | 
Subscription Information |  About Vidyya |  Vidyya Archives | 

Editor: Susan K. Boyer, RN
© Vidyya. All rights reserved.